EVENTS | VIEW CALENDAR
Life Technologies brings Compendia into the fold
CARLSBAD, Calif.—Life Technologies has announced the acquisition of cancer bioinformatics company Compendia Bioscience. While no financial terms were disclosed, Life Technologies expects the transaction to be neutral to earnings for this year and accretive to its overall ROIC by 2015. Following the acquisition, Compendia's existing business will continue to be led by its current management team. Arul Chinnaiyan, M.D., Ph.D., co-founder of Compendia, will serve as a strategic advisor to Life Technologies, and Daniel R. Rhodes, CEO and co-founder of Compendia, will join Life Technologies after the transaction is complete.
"We have created the optimal foundation to drive progress in personalized medicine," Gregory T. Lucier, chairman and CEO of Life Technologies, said in a statement. "By combining the acquisitions of Pinpoint Genomics, Navigenics and Compendia, we now possess the full spectrum capability to develop and commercialize high-value cancer diagnostics where there is currently great unmet need."
Compendia has extensive oncology expertise, with a data collection composed of mutation profiles, gene expression data and cellular biomarkers from more than 62,000 patients. Its Oncomine platform, a cloud- based analytics tool, includes Power Tools for interactive oncology data analysis, as well as Concepts Edition and Research Edition, web applications for the integration and unification of "high-throughput cancer profiling data so that target expression across a large volume of cancer types, subtypes and experiments can be assessed online, in seconds." Compendia's offering also includes OncoPredictor Discovery, which "identifies predictive biomarkers based on preclinical pharmacology," as well as services in translational medicine and target identification and validation. The company's OncoScore product allows customers to optimize their clinical trials process by the stratification of patients based on their genetic signatures.
Life Technologies plans to use Compendia's data collection and offerings to expand into additional areas of oncology.
"Compendia is highly regarded by its customers as a preeminent source of cancer biology expertise. That expertise will serve as a content engine to drive development of diagnostic content across the breadth of Life platforms," Ronnie Andrews, president of Medical Sciences at Life Technologies, said in a press release. "Initially, tests like Pervenio Lung RS will be offered as a service through our CLIA laboratory, but our longer-term goal is to commercialize diagnostic products on Life platforms for use in hospitals labs, where the majority of patients are treated. All patients should have access to an opportunity to benefit from the extensive knowledge base that has been gained through decades of research."
Once the transaction is complete, Life Technologies plans to develop a clinical version of Oncomine that will enable physicians to compare their patients' genetic signatures against large data sets in order to identify the most effective drug protocols. Compendia's oncology workflow will be incorporated into Life Technologies' Ion Reporter software to further develop its bioinformatics offering.
"Compendia has become an integral part of the pharmaceutical industry's cancer drug discovery programs, and in joining Life Technologies, we'll gain the opportunity to expand the utility of Compendia even further," Daniel R. Rhodes, CEO and co-founder of Compendia, said in a press release announcing the deal.